Contribution of Mesenchymal Stem Cells from Obese Adipose Tissue to PD-L1 Over-Expression and Breast Cancer Progression through Pathogenic Th17 Cell Activation.

IFNγ IL-17 PD-L1 adipose-tissue-derived mesenchymal stem cells breast cancer cancer progression immune check points obesity pathogenic Th17 cells

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
29 May 2023
Historique:
received: 30 03 2023
revised: 09 05 2023
accepted: 24 05 2023
medline: 10 6 2023
pubmed: 10 6 2023
entrez: 10 6 2023
Statut: epublish

Résumé

Obesity is a well-known risk factor for cancer. We have previously reported the role of adipose-tissue-derived mesenchymal stem cells from obese individuals (ob-ASC) in the promotion of pathogenic Th17 cells and immune check point (ICP) upregulation. Thus, we postulated herein that this mechanism could contribute to breast cancer (BC) aggressiveness. Conditioning medium (CM) from mitogen-activated ob-ASC and immune cell co-cultures were added to two human breast cancer cell line (BCCL) cultures. Expressions of pro-inflammatory cytokines, angiogenesis markers, metalloproteinases, and PD-L1 (a major ICP) were measured at the mRNA and/or protein levels. BCCL migration was explored in wound healing assays. Anti-cytokine neutralizing antibodies (Ab) were added to co-cultures. CM from ob-ASC/MNC co-cultures increased IL-1β, IL-8, IL-6, VEGF-A, MMP-9, and PD-L1 expressions in both BCCLs and accelerated their migration. The use of Abs demonstrated differential effects for IL-17A and IFNγ on BCCL pro-inflammatory cytokine over-expression or PD-L1 upregulation, respectively, but potentiating effects on BCCL migration. Finally, co-cultures with ob-ASC, but not lean ASC, enhanced PD-L1 expression. Our results demonstrate increased inflammation and ICP markers and accelerated BCCL migration following the activation of pathogenic Th17 cells by ob-ASC, which could represent a new mechanism linking obesity with BC progression.

Sections du résumé

BACKGROUND BACKGROUND
Obesity is a well-known risk factor for cancer. We have previously reported the role of adipose-tissue-derived mesenchymal stem cells from obese individuals (ob-ASC) in the promotion of pathogenic Th17 cells and immune check point (ICP) upregulation. Thus, we postulated herein that this mechanism could contribute to breast cancer (BC) aggressiveness.
METHODS METHODS
Conditioning medium (CM) from mitogen-activated ob-ASC and immune cell co-cultures were added to two human breast cancer cell line (BCCL) cultures. Expressions of pro-inflammatory cytokines, angiogenesis markers, metalloproteinases, and PD-L1 (a major ICP) were measured at the mRNA and/or protein levels. BCCL migration was explored in wound healing assays. Anti-cytokine neutralizing antibodies (Ab) were added to co-cultures.
RESULTS RESULTS
CM from ob-ASC/MNC co-cultures increased IL-1β, IL-8, IL-6, VEGF-A, MMP-9, and PD-L1 expressions in both BCCLs and accelerated their migration. The use of Abs demonstrated differential effects for IL-17A and IFNγ on BCCL pro-inflammatory cytokine over-expression or PD-L1 upregulation, respectively, but potentiating effects on BCCL migration. Finally, co-cultures with ob-ASC, but not lean ASC, enhanced PD-L1 expression.
CONCLUSIONS CONCLUSIONS
Our results demonstrate increased inflammation and ICP markers and accelerated BCCL migration following the activation of pathogenic Th17 cells by ob-ASC, which could represent a new mechanism linking obesity with BC progression.

Identifiants

pubmed: 37296927
pii: cancers15112963
doi: 10.3390/cancers15112963
pmc: PMC10252031
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Breast Dis. 2010;32(1-2):35-48
pubmed: 21778573
Front Oncol. 2021 May 14;11:618839
pubmed: 34055597
Lancet. 2020 Oct 10;396(10257):1090-1100
pubmed: 32966830
Nutrients. 2019 Nov 20;11(12):
pubmed: 31756890
Annu Rev Immunol. 2016 May 20;34:539-73
pubmed: 26927206
J Clin Invest. 2015 Sep;125(9):3384-91
pubmed: 26325035
Nat Med. 2002 Aug;8(8):793-800
pubmed: 12091876
Nat Med. 2019 Jan;25(1):141-151
pubmed: 30420753
Front Endocrinol (Lausanne). 2016 Apr 13;7:30
pubmed: 27148161
Breast Cancer Res Treat. 2010 Oct;123(3):627-35
pubmed: 20571870
Lancet. 2014 Aug 30;384(9945):755-65
pubmed: 25129328
Front Immunol. 2020 Oct 21;11:568931
pubmed: 33193345
Mol Nutr Food Res. 2019 Jun;63(11):e1801148
pubmed: 30848861
Cells. 2023 Jan 17;12(3):
pubmed: 36766689
Adv Nutr. 2016 Jan 15;7(1):66-75
pubmed: 26773015
Cancer Discov. 2019 Oct;9(10):1422-1437
pubmed: 31340937
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
J Exp Med. 2009 Jul 6;206(7):1457-64
pubmed: 19564351
Breast Cancer Res Treat. 2013 Jan;137(1):307-14
pubmed: 23179600
Am J Clin Oncol. 2016 Feb;39(1):98-106
pubmed: 26558876
Clin Cancer Res. 2019 May 1;25(9):2769-2782
pubmed: 30670488
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Diabetes. 2015 Jul;64(7):2477-88
pubmed: 25765019
Nat Med. 2009 Aug;15(8):914-20
pubmed: 19633658
J Exp Med. 2000 Oct 2;192(7):1027-34
pubmed: 11015443
Cytotherapy. 2013 Jun;15(6):641-8
pubmed: 23570660
J Immunother Cancer. 2019 Nov 15;7(1):305
pubmed: 31730010
Immunol Lett. 2017 Apr;184:7-14
pubmed: 28223102
Cancer Res. 2012 Oct 15;72(20):5198-208
pubmed: 23071132
Pathobiology. 1999;67(1):12-8
pubmed: 9873223
Anticancer Res. 2015 Jun;35(6):3147-54
pubmed: 26026074
Cell. 2016 Dec 1;167(6):1540-1554.e12
pubmed: 27912061
Cancer Epidemiol Biomarkers Prev. 2011 Nov;20(11):2461-8
pubmed: 21930958
Nucleic Acids Res. 2001 May 1;29(9):e45
pubmed: 11328886
Nat Med. 2009 Aug;15(8):921-9
pubmed: 19633657
Oncogene. 2019 Mar;38(11):1979-1988
pubmed: 30361686
Nat Rev Cancer. 2011 Nov 24;11(12):886-95
pubmed: 22113164
Cancers (Basel). 2022 Aug 12;14(16):
pubmed: 36010901
Cell Rep. 2017 May 9;19(6):1189-1201
pubmed: 28494868
J Clin Med. 2017 Jul 14;6(7):
pubmed: 28708082
Braz J Med Biol Res. 2013 Sep;46(9):758-64
pubmed: 24068191
J Interferon Cytokine Res. 2013 Oct;33(10):563-70
pubmed: 23697558
Breast Cancer Res Treat. 2020 Jul;182(2):267-282
pubmed: 32445177
N Engl J Med. 2020 Feb 27;382(9):810-821
pubmed: 32101663
Clin Cancer Res. 2015 Feb 15;21(4):687-92
pubmed: 25501578
Cells. 2021 Oct 03;10(10):
pubmed: 34685625
JCI Insight. 2021 Apr 22;6(8):
pubmed: 33884962
Breast Cancer Res. 2011 Sep 20;13(5):R91
pubmed: 21933397

Auteurs

Ferdinand Blangero (F)

CarMeN Laboratory, INSERM U1060, INRAE U1397, University Claude Bernard Lyon 1, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, 69310 Pïerre Bénite, France.

Maud Robert (M)

CarMeN Laboratory, INSERM U1060, INRAE U1397, University Claude Bernard Lyon 1, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, 69310 Pïerre Bénite, France.
Bariatric Surgery Department, Edouard Herriot Hospital, 69003 Lyon, France.

Thomas Andraud (T)

CarMeN Laboratory, INSERM U1060, INRAE U1397, University Claude Bernard Lyon 1, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, 69310 Pïerre Bénite, France.

Charles Dumontet (C)

Center of Research in Cancerology of Lyon, INSERM U1052, CNRS 5286, University Claude Bernard Lyon 1, Centre Léon Berard, 69008 Lyon, France.

Hubert Vidal (H)

CarMeN Laboratory, INSERM U1060, INRAE U1397, University Claude Bernard Lyon 1, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, 69310 Pïerre Bénite, France.

Assia Eljaafari (A)

CarMeN Laboratory, INSERM U1060, INRAE U1397, University Claude Bernard Lyon 1, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, 69310 Pïerre Bénite, France.
Research Department, Hospices Civils de Lyon, 69002 Lyon, France.

Classifications MeSH